Tice BCG
TICE BCG is a live, attenuated strain of Mycobacterium bovis. When introduced into the bladder (intravesically), it acts as a local immunotherapy by stimulating an immune response that targets and destroys cancer cells in the bladder lining.
Dosage by Body Weight
The standard adult dose is one reconstituted vial (approx. 50 mg) instilled intravesically once a week for 6 weeks (induction phase), followed by maintenance therapy as determined by an oncologist. Not for intravenous, subcutaneous, or intramuscular administration.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Not used in this weight range.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Not used in this weight range.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Not used in this weight range.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Not used in this weight range.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Not used in this weight range.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Not used in this weight range. |
| 5-7 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Not used in this weight range. |
| 8-10 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Not used in this weight range. |
| 11-15 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Not used in this weight range. |
| 16-20 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Not used in this weight range. |
Formulation
Purpose
Used for the intravesical treatment and prophylaxis of clinically superficial urinary bladder cancer, specifically carcinoma in situ (CIS) and primary or recurrent stage Ta or T1 papillary tumors.
Generic Name
Bacillus Calmette-Guerin (TICE strain)Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.